CNBC's Meg Tirrell, and Michael Pellini, Foundation Medicine president & CEO, discuss the benefits of Roche's majority stake in Foundation Medicine.
Healthcare M&A looks set to be strong again this year, following deals from Shire and Roche. But Goldman Sachs says energy's a sector to watch too.
Swiss drug maker Roche plans to acquire a majority stake in Foundation Medicine by buying a combination of outstanding and newly issued shares.
The JPMorgan health care conference hadn't even officially begun when the first big piece of news of the week hit: Irish drugmaker Shire said Sunday morning it's purchasing orphan-drug company NPS Pharmaceuticals for $5.2 billion.
European shares closed mixed on Monday, with Greece struck by renewed political uncertainty after its politicians failed to agree on a new president.
European shares closed mixed on Friday, with Italian banking stocks and the health care sector weighing on wider benchmarks.
The health-care sector tends to outperform the overall market during flu season. Who else stands to gain?
There are few new cancer drugs to treat kids, and not much research is being done.
Germany's Merck KGaA said Monday it struck an alliance over cancer immunotherapy drugs with Pfizer, triggering an upfront payment of $850 million by the U.S. drugmaker.
The U.S. FDA has revoked a tentative approval for India's Ranbaxy to make a cheap copy of AstraZeneca's heartburn drug Nexium.
Alibaba muscled ahead of Wal-Mart by one important measure, when its market valuation surpassed the retailer by revenues. The Financial Times reports.
Drugmakers are racing to develop vaccines and drugs to address Ebola, betting that governments and aid groups will foot the bill.
European shares closed lower on Thursday after trimming losses, tracking U.S. markets which partially recovered after visiting correction territory.
Roche reported third quarter sales of 11.78 billion Swiss francs ($12.29 billion) on Thursday, above analysts' forecasts of 11.58 billion Swiss francs in a Reuters poll.
Severin Schwan, CEO of Roche Group, says the company's "fundamental strategy" has not changed and is looking at "targeted" M&A deals.
Severin Schwan, CEO of Roche Group, says the world was surprised by the "magnitude" of the Ebola outbreak.
Mergers have hit a level not seen since the financial crisis, and there is a way for investors to profit from the M&A frenzy—in one trade.
Data released at the European Society of Medical Oncology meeting over the weekend showed much progress in fighting a number of cancers. Here's what investors need to know.
A breast cancer drug from Roche known as Perjeta helped patients live nearly 16 months longer compared with Herceptin and chemotherapy alone. CNBC's Meg Tirrell provides insight to the data.
Looking for new ideas as you put money to work in the stock market? Jim Cramer has plenty of them!